EUVIMEDEUVIMED entdecken
Crossref

Exploring Thiazolidinedione-Naphthalene Analogues as Potential Antidiabetic Agents: Design, Synthesis, Molecular Docking and In-vitro Evaluation

Sharfuddin Mohd, Vikas Sharma, Vancha Harish, Rakesh Kumar, Govindaiah Pilli

Cell Biochemistry and Biophysics · 2024

DOI: 10.1007/s12013-024-01632-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biochemistry and Biophysics, 2024. Verfasst von Sharfuddin Mohd und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of pharmaceutical sciences, Lovely Professional University, Phagwara, Punjab, India. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Molecular Docking Simulation, Thiazolidinediones, Drug Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thiazolidinedione-naphthalene analogues were synthesized and evaluated for antidiabetic activity as Pancreatic α-Amylase (PAA) and intestinal α-glucosidase (IAG) inhibitors. The activity of the compounds (14a-g,17a-k) is compared with acarbose as the standard drug and all the compounds shows good to moderate antidiabetic activity. In-vitro PAA and IAG inhibition assay is performed for the all compounds, the compounds 17e shows superior PAA and IAG inhibitory activity with respective to standard (IC50 = 12.455 ± 0.04 μM and 9.145 ± 0. 01 μM). The molecular interaction with PAA and IAG protein was also studied with the help of molecular docking studies using AutoDock software. while SwissADME and Osiris property explorer tools computed in-silico drug likeliness and toxicity properties. The in-silico results confirmed the 17e molecule as a superior drug with high binding affinity and good drug likeness against PAA and IAG, confirming in-vitro results. We also studied antioxidant activity (AOA) of all synthesized compounds and results confined that the compound 14g and 17e has good antioxidant potential IC50 = 8.04 ± 0.02 μM and 6.36 ± 0.03 μM respectively among all compounds. In conclusion, in-vitro, in-silico antidiabetic and antioxidant studies revealed 17e compound was found to be potential compound.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsMolecular Docking SimulationThiazolidinedionesDrug DesignNaphthalenesalpha-Glucosidasesalpha-AmylasesGlycoside Hydrolase InhibitorsAntioxidantsHumansPancreas

Stichwörter der Autor:innen

AntioxidantDiabetesIntestinal α-glucosidaseNaphthalenePancreatic α-amylaseThiazolidinediones

Substanzen

Hypoglycemic AgentsThiazolidinedionesalpha-Glucosidasesalpha-AmylasesNaphthalenesGlycoside Hydrolase InhibitorsAntioxidants

Autor:innen und Institutionen

  • School of pharmaceutical sciences, Lovely Professional University, Phagwara, Punjab, India.
  • Faculty of medicine, Department of Pathology, Wayne state University, Detroit, MI, USA. govipharma@gmail.com.

Zitieren

APA

Mohd, S., Sharma, V., Harish, V., Kumar, R., & Pilli, G. (2024). Exploring Thiazolidinedione-Naphthalene Analogues as Potential Antidiabetic Agents: Design, Synthesis, Molecular Docking and In-vitro Evaluation. Cell Biochemistry and Biophysics. https://doi.org/10.1007/s12013-024-01632-y

Vancouver

Mohd S, Sharma V, Harish V, Kumar R, Pilli G. Exploring Thiazolidinedione-Naphthalene Analogues as Potential Antidiabetic Agents: Design, Synthesis, Molecular Docking and In-vitro Evaluation. Cell Biochemistry and Biophysics. 2024. doi:10.1007/s12013-024-01632-y

BibTeX
@article{Mohd2024,
  author = {Mohd, Sharfuddin and Sharma, Vikas and Harish, Vancha and Kumar, Rakesh and Pilli, Govindaiah},
  title = {Exploring Thiazolidinedione-Naphthalene Analogues as Potential Antidiabetic Agents: Design, Synthesis, Molecular Docking and In-vitro Evaluation},
  journal = {Cell Biochemistry and Biophysics},
  year = {2024},
  doi = {10.1007/s12013-024-01632-y}
}
Kostenlos starten →